rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2015-661-670rsp-2160Research ArticleИНФОРМАЦИЯINFORMATIONЕвропейский конгресс ревматологов, Рим (10–13 июня 2015 г.), – проблемы ревматоидного артритаTHE EUROPEAN CONGRESS OF RHEUMATOLOGY, ROME (10–13 JUNE 2015): PROBLEMS OF RHEUMATOID ARTHRITISАвдееваА. С.AvdeevaA. S.9056249400@mail.ruДенисовЛ. Н.DenisovL. N.НасоновЕ. Л.NasonovE. L.ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian FederationФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, Москва, Россия 119991 Москва, ул. Трубецкая, 8, стр. 2РоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522 I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia 8, Trubetskaya St., Build. 2, Moscow 119991Russian Federation201506022016536661670Copyright © Авдеева А.С., Денисов Л.Н., Насонов Е.Л., 20162016Авдеева А.С., Денисов Л.Н., Насонов Е.Л.Avdeeva A.S., Denisov L.N., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2160

10–13 июня 2015 г. в Риме проходил ежегодный 16-й Европейский конгресс ревматологов, который, несомненно, является центральным событием мировой ревматологии. В его работе приняли участие около 14 тыс. делегатов: врачей, ученых, работников здравоохранения, пациентов, представляющих более чем 100 стран мира. Были рассмотрены 4300 тезисов, 82% из них отобраны для публикации. Программа конгресса была чрезвычайно многообразна, она включала обсуждение новых данных, касающихся диагностики и лечения наиболее распространенных ревматических заболеваний, проблем их этиологии и патогенеза, персонифицированной терапии и многое другое. Более подробно в данном сообщении представлены материалы, отражающие современные тенденции в лечении ревматоидного артрита.

The 16th Annual European Congress of Rheumatology, which is indubitably the central event of international rheumatology, took place in Rome on 10–13 June 2015. It was attended by around 14,000 delegates (physicians, healthcare workers, patients) from more than 100 countries of the world. A total of 4,300 theses were considered; 82% of them were selected to be published. The program of the congress was extremely diverse; it included discussion of new data on the diagnosis and treatment of the most common rheumatic diseases, their etiology and pathogenesis, personified therapy, and many other problems. This communication presents in more detail materials reflecting current trends in the treatment of rheumatoid arthritis.

Европейский конгресс ревматологовEULARревматоидный артритEuropean Congress of RheumatologyEULARrheumatoid arthritisReferencesLu L, Choi HK, Schoenfeld SR, et al. Improved survival in rheumatoid arthritis: a general population-based study. Ann Rheum Dis. 2015;74(Suppl 2):137. doi: 10.1136/annrheumdis-2015-eular.3507Lu L, Choi HK, Schoenfeld SR, et al. Improved survival in rheumatoid arthritis: a general population-based study. Ann Rheum Dis. 2015;74(Suppl 2):137. doi: 10.1136/annrheumdis-2015-eular.3507Ajeganova S, Hafströ m I, Svensson B, et al. Failure to achieve early remission augments risk of mortality in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):140. doi: 10.1136/annrheumdis-2015-eular.5125Ajeganova S, Hafströ m I, Svensson B, et al. Failure to achieve early remission augments risk of mortality in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):140. doi: 10.1136/annrheumdis-2015-eular.5125Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. Rheumatology (Oxford). 2000;39:1031–6. doi: 10.1093/rheumatology/39.9.1031Svensson B, Schaufelberger C, Teleman A, Theander J. Remission and response to early treatment of RA assessed by the Disease Activity Score. Rheumatology (Oxford). 2000;39:1031–6. doi: 10.1093/rheumatology/39.9.1031Svensson B, Boonen A, Albertsson K, et al.; for the BARFOT Study Group. Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum. 2005;52:3360–70. doi: 10.1002/art.21298Svensson B, Boonen A, Albertsson K, et al.; for the BARFOT Study Group. Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum. 2005;52:3360–70. doi: 10.1002/art.21298Ajeganova S, Svensson B, Hafströ m I, on behalf of the BARFOT Study Group. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow- up of a 2-year randomised trial. BMJ Open. 2014;4:e004259. doi: 10.1136/bmjopen-2013-004259Ajeganova S, Svensson B, Hafströ m I, on behalf of the BARFOT Study Group. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow- up of a 2-year randomised trial. BMJ Open. 2014;4:e004259. doi: 10.1136/bmjopen-2013-004259Emery P, Roy M, Fleischmann RM, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60:2272–83. doi: 10.1002/art.24638Emery P, Roy M, Fleischmann RM, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60:2272–83. doi: 10.1002/art.24638Emery R, Fleischmann R, Xu S,et al. Treatment target status at 6 months and long-term outcomes at 5 years: analysis of methotrexate-naive patients with rheumatoid arthritis in the GO-BEFORE trial. Ann Rheum Dis. 2015;74(Suppl 2):711. doi: 10.1136/annrheumdis-2015-eular.3647Emery R, Fleischmann R, Xu S,et al. Treatment target status at 6 months and long-term outcomes at 5 years: analysis of methotrexate-naive patients with rheumatoid arthritis in the GO-BEFORE trial. Ann Rheum Dis. 2015;74(Suppl 2):711. doi: 10.1136/annrheumdis-2015-eular.3647Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509. doi: 10.1136/annrheumdis-2013-204573Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509. doi: 10.1136/annrheumdis-2013-204573Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России –2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477–94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):477–94 (In Russ.)]. doi: 10.14412/1995-4484-2014-477-494Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России –2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477–94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):477–94 (In Russ.)]. doi: 10.14412/1995-4484-2014-477-494Verschueren P, de Cock D, Corluy L, et al. Remission induction with DMARD combinations and glucocorticoids is not superior to remission induction with MTX monotherapy and glucocorticoids: week 52 results of the high-risk group from the CARERA trial. Ann Rheum Dis. 2015;74(Suppl 2):139. doi: 10.1136/annrheumdis-2015-eular.4018Verschueren P, de Cock D, Corluy L, et al. Remission induction with DMARD combinations and glucocorticoids is not superior to remission induction with MTX monotherapy and glucocorticoids: week 52 results of the high-risk group from the CARERA trial. Ann Rheum Dis. 2015;74(Suppl 2):139. doi: 10.1136/annrheumdis-2015-eular.4018Verschueren P, de Cock D, Corlue L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27–34. doi:10.1136/annrheumdis-2014-205489Verschueren P, de Cock D, Corlue L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27–34. doi:10.1136/annrheumdis-2014-205489Verschueren P, de Cock D, Corlue L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015:17:29. doi: 10.1186/s13075-015-0611-8Verschueren P, de Cock D, Corlue L, et al. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther. 2015:17:29. doi: 10.1186/s13075-015-0611-8De Cock D, Corluy L, Joos R, et al. Low-risk patients also benefit from remission induction treatment in early rheumatoid arthritis: week 52 results from the CARERA trial. Ann Rheum Dis. 2015;74(Suppl 2):236. doi: 10.1136/annrheumdis-2015-eular.3984De Cock D, Corluy L, Joos R, et al. Low-risk patients also benefit from remission induction treatment in early rheumatoid arthritis: week 52 results from the CARERA trial. Ann Rheum Dis. 2015;74(Suppl 2):236. doi: 10.1136/annrheumdis-2015-eular.3984Kuijper T, Luime J, de Jong P, et al. Tapering DMARDs in the TREACH trial – flare rates, sustained remission and radiological progression. Ann Rheum Dis. 2015;74(Suppl 2):76. doi: 10.1136/annrheumdis-2015-eular.5218Kuijper T, Luime J, de Jong P, et al. Tapering DMARDs in the TREACH trial – flare rates, sustained remission and radiological progression. Ann Rheum Dis. 2015;74(Suppl 2):76. doi: 10.1136/annrheumdis-2015-eular.5218De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72–8. doi: 10.1136/annrheumdis-2011-201162De Jong PH, Hazes JM, Barenndregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis. 2013;72:72–8. doi: 10.1136/annrheumdis-2011-201162De Jong PH, Hazes JM, Han HK, et al. Randomized comparison of initial triple DMAR therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331–9. doi: 10.1136/annrheumdis-2013-204788De Jong PH, Hazes JM, Han HK, et al. Randomized comparison of initial triple DMAR therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis. 2014;73:1331–9. doi: 10.1136/annrheumdis-2013-204788Bijlsma JW, Welsing PM, Woodworth TG, et al. Rapid and sustained remission in early rheumatoid arthritis (RA) treated to target with tocilizumab, methotrexate, or their combination: the U-ACTEarly Strategy Study. Ann Rheum Dis. 2015;74(Suppl 2):77. doi: 10.1136/annrheumdis-2015-eular.2287Bijlsma JW, Welsing PM, Woodworth TG, et al. Rapid and sustained remission in early rheumatoid arthritis (RA) treated to target with tocilizumab, methotrexate, or their combination: the U-ACTEarly Strategy Study. Ann Rheum Dis. 2015;74(Suppl 2):77. doi: 10.1136/annrheumdis-2015-eular.2287Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-207628Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-207628Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthritis Rheum. 2011;62:43–52. doi: 10.1002/art.27740Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of remission: the role of acute phase reactants. Arthritis Rheum. 2011;62:43–52. doi: 10.1002/art.27740Jorgensen TS, Tarp S, Furst DE, et al. Added-value of combining methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2015;74(Suppl 2):239. doi: 10.1136/annrheumdis-2015-eular.3396Jorgensen TS, Tarp S, Furst DE, et al. Added-value of combining methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2015;74(Suppl 2):239. doi: 10.1136/annrheumdis-2015-eular.3396Emery P, Bingham CO, Burmester GR, et al. The first study of certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1493Emery P, Bingham CO, Burmester GR, et al. The first study of certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients led to sustained clinical response and inhibition of radiographic progression at 52 weeks: the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1493Emery P, Bingham CO, Burmester GR, et al. Improvements in patient-reported outcomes and workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients: results from the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1499Emery P, Bingham CO, Burmester GR, et al. Improvements in patient-reported outcomes and workplace and household productivity following 52 weeks of treatment with certolizumab pegol in combination with methotrexate in DMARD-naive early rheumatoid arthritis patients: results from the C-EARLY randomized, double-blind, controlled phase 3 study. Ann Rheum Dis. 2015;74(Suppl 2):712. doi: 10.1136/annrheumdis-2015-eular.1499Emery P, Burmester GR, Bykerk V, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b multicenter, randomized, active-controlled AVERT study of 24 months, with a 12 months, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26. doi: 10.1136/annrheumdis-2014-206106Emery P, Burmester GR, Bykerk V, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b multicenter, randomized, active-controlled AVERT study of 24 months, with a 12 months, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26. doi: 10.1136/annrheumdis-2014-206106Burmester G, Furst DE, Combe BG, et al. Stringent criteria for low disease activity and remission after 12 month of treatment, and after treatment withdrawal, with abatacept monotherapy, abatacept with methotrexate or methotrexate alone in early rheumatoid arthritis. Arthritis Rheum. 2014;66(Suppl):2468 (abst).Burmester G, Furst DE, Combe BG, et al. Stringent criteria for low disease activity and remission after 12 month of treatment, and after treatment withdrawal, with abatacept monotherapy, abatacept with methotrexate or methotrexate alone in early rheumatoid arthritis. Arthritis Rheum. 2014;66(Suppl):2468 (abst).Bykerk VP, Burmester GR, Combe BG, et al. On drug and drugfree remission by baseline disease duration in the AVERT trial: abatacept versus methotrexate comparison in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):477. doi: 10.1136/annrheumdis-2015-eular.2071Bykerk VP, Burmester GR, Combe BG, et al. On drug and drugfree remission by baseline disease duration in the AVERT trial: abatacept versus methotrexate comparison in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):477. doi: 10.1136/annrheumdis-2015-eular.2071Mehta P, Davy K, Williamson R, et al. Meta-analysis of randomised controlled trials of biologics in DMARDS-naive and DMARDS-inadequate responder subjects with rheumatoid arthritis: efficacy and safety. Ann Rheum Dis. 2015;74(Suppl 2):239. doi: 10.1136/annrheumdis-2015-eular.2358Mehta P, Davy K, Williamson R, et al. Meta-analysis of randomised controlled trials of biologics in DMARDS-naive and DMARDS-inadequate responder subjects with rheumatoid arthritis: efficacy and safety. Ann Rheum Dis. 2015;74(Suppl 2):239. doi: 10.1136/annrheumdis-2015-eular.2358Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015. doi: 10.1038/nrrheum.2015.8Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015. doi: 10.1038/nrrheum.2015.8Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al. Randomized trial of stopping tnf-inhibitors in rheumatoid arthritis patients with stable remission or low disease activity in the Netherlands. Ann Rheum Dis. 2015;74(Suppl 2):709. doi: 10.1136/annrheumdis-2015-eular.2388Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, et al. Randomized trial of stopping tnf-inhibitors in rheumatoid arthritis patients with stable remission or low disease activity in the Netherlands. Ann Rheum Dis. 2015;74(Suppl 2):709. doi: 10.1136/annrheumdis-2015-eular.2388Hernandez MV, Gomez-Puerta JA, Canete JD, et al. Biologic DMARDs in patients with rheumatoid arthritis on a Spanish registry: predictors of therapy discontinuation due to remission. Ann Rheum Dis. 2015;74(Suppl 2):464. doi: 10.1136/annrheumdis-2015-eular.2729Hernandez MV, Gomez-Puerta JA, Canete JD, et al. Biologic DMARDs in patients with rheumatoid arthritis on a Spanish registry: predictors of therapy discontinuation due to remission. Ann Rheum Dis. 2015;74(Suppl 2):464. doi: 10.1136/annrheumdis-2015-eular.2729Desouches S, Avenel G, Kozyreff M, et al. Experience of spacing and withdrawal of biological agents in rheumatoid arthritis patients in remission: identification of relapse predictive factors. Ann Rheum Dis. 2015;74(Suppl 2):470. doi: 10.1136/annrheumdis-2015- eular.3533Desouches S, Avenel G, Kozyreff M, et al. Experience of spacing and withdrawal of biological agents in rheumatoid arthritis patients in remission: identification of relapse predictive factors. Ann Rheum Dis. 2015;74(Suppl 2):470. doi: 10.1136/annrheumdis-2015- eular.3533Okano T, Inui K, Tada M, et al. Medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity – KABUKI study. Ann Rheum Dis. 2015;74(Suppl 2):471. doi: 10.1136/annrheumdis-2015-eular.2609Okano T, Inui K, Tada M, et al. Medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity – KABUKI study. Ann Rheum Dis. 2015;74(Suppl 2):471. doi: 10.1136/annrheumdis-2015-eular.2609Galloway JB, Kingsley G, Ma M, et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Ann Rheum Dis. 2015;74(Suppl 2):706. doi: 10.1136/annrheumdis-2015-eular.4684Galloway JB, Kingsley G, Ma M, et al. Optimising treatment with TNF inhibitors in rheumatoid arthritis with different dose tapering strategies: the OPTTIRA trial. Ann Rheum Dis. 2015;74(Suppl 2):706. doi: 10.1136/annrheumdis-2015-eular.4684Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2014-206439Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2014-206439Haschka J, Englbrecht M, Hueber AJ, et al. RETRO – study of reduction of therapy in patients with rheumatoid arthritis in ongoing remission. Ann Rheum Dis. 2015;74(Suppl 2):668. doi: 10.1136/annrheumdis-2015-eular.5961Haschka J, Englbrecht M, Hueber AJ, et al. RETRO – study of reduction of therapy in patients with rheumatoid arthritis in ongoing remission. Ann Rheum Dis. 2015;74(Suppl 2):668. doi: 10.1136/annrheumdis-2015-eular.5961Espinosa F, Arce-Salinas CA, Alfaro-Lara R. Systematic review and meta-analysis on the efficacy of leflunomide vs. methotrexate as monotherapy in patients with rheumatoid arthritis (RA). Ann Rheum Dis. 2015;74(Suppl 2):739. doi: 10.1136/annrheumdis-2015-eular.3431Espinosa F, Arce-Salinas CA, Alfaro-Lara R. Systematic review and meta-analysis on the efficacy of leflunomide vs. methotrexate as monotherapy in patients with rheumatoid arthritis (RA). Ann Rheum Dis. 2015;74(Suppl 2):739. doi: 10.1136/annrheumdis-2015-eular.3431Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(прил. 1):64–76 [Nasonov EL. Methotrexate for rheumatoid arthritis – 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(Suppl 1):64–76 (In Russ.)].Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(прил. 1):64–76 [Nasonov EL. Methotrexate for rheumatoid arthritis – 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(Suppl 1):64–76 (In Russ.)].Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26]. doi: 10.14412/1995-4484-2014-8-26Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26]. doi: 10.14412/1995-4484-2014-8-26Levitsky A, Erlandsson M, van Vollenhoven RF, et al. Serum survivin predicts treatment response in active rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):224. doi: 10.1136/annrheumdis-2015-eular.3151Levitsky A, Erlandsson M, van Vollenhoven RF, et al. Serum survivin predicts treatment response in active rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):224. doi: 10.1136/annrheumdis-2015-eular.3151Van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomized trial. Lancet. 2009;374:459–66. doi: 10.1016/S0140-6736(09)60944-2Van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomized trial. Lancet. 2009;374:459–66. doi: 10.1016/S0140-6736(09)60944-2Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379:1712–20. doi: 10.1016/S0140-6736(12)60027-0Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379:1712–20. doi: 10.1016/S0140-6736(12)60027-0Gu YJ, Jin SD, Wang F, et al. Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. 2014;68:471–5. doi: 10.1016/j.biopha.2014.03.010Gu YJ, Jin SD, Wang F, et al. Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. 2014;68:471–5. doi: 10.1016/j.biopha.2014.03.010Chun-Lai T, Murad S, Erlandsson MC, et al. Recognizing rheumatoid arthritis: oncoprotein survivin opens new possibilities: a population-based case-control study. Medicine (Baltimore). 2015;94:e468. doi: 10.1097/MD.0000000000000468Chun-Lai T, Murad S, Erlandsson MC, et al. Recognizing rheumatoid arthritis: oncoprotein survivin opens new possibilities: a population-based case-control study. Medicine (Baltimore). 2015;94:e468. doi: 10.1097/MD.0000000000000468Cregan S, Creevey K, McGarry T, et al. The role of epigenetics in determining the clinical response to methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):897. doi: 10.1136/annrheumdis-2015-eular.1825Cregan S, Creevey K, McGarry T, et al. The role of epigenetics in determining the clinical response to methotrexate for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):897. doi: 10.1136/annrheumdis-2015-eular.1825Neumann E , Lefevre S, Zimmermann B, et al. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med. 2010;16:458–468. doi: 10.10.1016/j.molmed.2010.07.004Neumann E , Lefevre S, Zimmermann B, et al. Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med. 2010;16:458–468. doi: 10.10.1016/j.molmed.2010.07.004Cribbs AP, Kennedy A, Penn H, et al. Treg cell function in rheumatoid arthritis is compromised by CTLA-4 promoter methylation resulting in a failure to activate the indolamine 2,3-deoxygenase pathway. Arthritis Rheum. 2014; 66:2344–54. doi: 10.1002/art.38715Cribbs AP, Kennedy A, Penn H, et al. Treg cell function in rheumatoid arthritis is compromised by CTLA-4 promoter methylation resulting in a failure to activate the indolamine 2,3-deoxygenase pathway. Arthritis Rheum. 2014; 66:2344–54. doi: 10.1002/art.38715Cribbs AP, Kennedy A, Penn H, et al. Methotrexate restores regulatory T cell function through demethelation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheum. 2015;67:1182–92. doi: 10.1002/art.39031Cribbs AP, Kennedy A, Penn H, et al. Methotrexate restores regulatory T cell function through demethelation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheum. 2015;67:1182–92. doi: 10.1002/art.39031Hollan I, Vuong TT, Reine TM, et al. Anti-rheumatic therapy reduces syndecan-1 shedding in rheumatoid arthritis (RA). Ann Rheum Dis. 2015;74(Suppl 2):1011. doi: 10.1136/annrheumdis-2015-eular.3266Hollan I, Vuong TT, Reine TM, et al. Anti-rheumatic therapy reduces syndecan-1 shedding in rheumatoid arthritis (RA). Ann Rheum Dis. 2015;74(Suppl 2):1011. doi: 10.1136/annrheumdis-2015-eular.3266Lee JJ, Bykerk VP, Dresser GK, et al. Does methotrexate lower serum uric acid levels? Data from the CATCH cohort. Ann Rheum Dis. 2015;74(Suppl 2):248. doi: 10.1136/annrheumdis-2015-eular.2595Lee JJ, Bykerk VP, Dresser GK, et al. Does methotrexate lower serum uric acid levels? Data from the CATCH cohort. Ann Rheum Dis. 2015;74(Suppl 2):248. doi: 10.1136/annrheumdis-2015-eular.2595Asai S, Takahashi N, Funahashi K, et al. Effects of concomitant methotrexate on the long-term outcome of knee joint destruction in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors. Ann Rheum Dis. 2015;74(Suppl 2):220. doi: 10.1136/annrheumdis-2015-eular.1337Asai S, Takahashi N, Funahashi K, et al. Effects of concomitant methotrexate on the long-term outcome of knee joint destruction in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors. Ann Rheum Dis. 2015;74(Suppl 2):220. doi: 10.1136/annrheumdis-2015-eular.1337Kawasaki T, Okumura N, Mimura T, et al. Hip joint protection and falling numbers of total hip arthroplasties in cases of rheumatoid arthritis: does medication work? Ann Rheum Dis. 2015;74(Suppl 2):1069. doi: 10.1136/annrheumdis-2015-eular.3712Kawasaki T, Okumura N, Mimura T, et al. Hip joint protection and falling numbers of total hip arthroplasties in cases of rheumatoid arthritis: does medication work? Ann Rheum Dis. 2015;74(Suppl 2):1069. doi: 10.1136/annrheumdis-2015-eular.3712Widdifield J, Moura C, Wang Y, et al. The influence of drug exposures on joint surgeries in rheumatoid arthritis patients: crossprovincial comparisons. Ann Rheum Dis. 2015;74(Suppl 2):72. doi: 10.1136/annrheumdis-2015-eular.4981Widdifield J, Moura C, Wang Y, et al. The influence of drug exposures on joint surgeries in rheumatoid arthritis patients: crossprovincial comparisons. Ann Rheum Dis. 2015;74(Suppl 2):72. doi: 10.1136/annrheumdis-2015-eular.4981Dolan L, Joshi A. A true to life study on effects of switching from oral to subcutaneous methotrexate. Ann Rheum Dis. 2015;74(Suppl 2):1065. doi: 10.1136/annrheumdis-2015-eular.1058Dolan L, Joshi A. A true to life study on effects of switching from oral to subcutaneous methotrexate. Ann Rheum Dis. 2015;74(Suppl 2):1065. doi: 10.1136/annrheumdis-2015-eular.1058Studenic P, Alasti F, Smolen JS, et al. Kidney function and effectiveness of methotrexate treatment in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):453. doi: 10.1136/annrheumdis- 2015-eular.5293Studenic P, Alasti F, Smolen JS, et al. Kidney function and effectiveness of methotrexate treatment in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):453. doi: 10.1136/annrheumdis- 2015-eular.5293Conigliaro P, Triggianese P, Sunzini F, et al. Treatment targets with first line biological agents in early and longstanding rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):467. doi: 10.1136/annrheumdis-2015-eular.6397Conigliaro P, Triggianese P, Sunzini F, et al. Treatment targets with first line biological agents in early and longstanding rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):467. doi: 10.1136/annrheumdis-2015-eular.6397Lamers-Karnebeek FBG, Jansen T, van Riel P, et al. Ultrasonography as predictor for flare in rheumatoid arthritis patients with low disease activity: nine month results from POETUS- study. Ann Rheum Dis. 2015;74(Suppl 2):140. doi: 10.1136/annrheumdis-2015-eular.5185Lamers-Karnebeek FBG, Jansen T, van Riel P, et al. Ultrasonography as predictor for flare in rheumatoid arthritis patients with low disease activity: nine month results from POETUS- study. Ann Rheum Dis. 2015;74(Suppl 2):140. doi: 10.1136/annrheumdis-2015-eular.5185Avila MG, Alonso A, Lopez Lasanta M, et al. Long-term followup study of biological therapy discontinuation in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):475. doi: 10.1136/annrheumdis-2015-eular.4078Avila MG, Alonso A, Lopez Lasanta M, et al. Long-term followup study of biological therapy discontinuation in rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):475. doi: 10.1136/annrheumdis-2015-eular.4078Hattori Y, Kaneko A, Kida D, et al. Retention rate and discontinuation due to efficacy and safety in Japanese patients with rheumatoid arthritis receiving adalimumab therapy: a multicenter study. Ann Rheum Dis. 2015;74(Suppl 2):472. doi: 10.1136/annrheumdis- 2015-eular.1098Hattori Y, Kaneko A, Kida D, et al. Retention rate and discontinuation due to efficacy and safety in Japanese patients with rheumatoid arthritis receiving adalimumab therapy: a multicenter study. Ann Rheum Dis. 2015;74(Suppl 2):472. doi: 10.1136/annrheumdis- 2015-eular.1098Jani M, Barton A, Warren R, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–22. doi: 10.1093/rheumatology/ket260Jani M, Barton A, Warren R, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–22. doi: 10.1093/rheumatology/ket260Александрова ЕН, Насонов ЕЛ. Иммуногенность ингибиторов фактора некроза опухоли α при лечении ревматоидного артрита. Научно-практическая ревматология. 2012;53(прил. 4):22–7 [Aleksandrova EN, Nasonov EL. Immunogenicity inhibitors of tumor necrosis factor α in the treatment of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;53(Suppl 4):22–7 (In Russ.)].Александрова ЕН, Насонов ЕЛ. Иммуногенность ингибиторов фактора некроза опухоли α при лечении ревматоидного артрита. Научно-практическая ревматология. 2012;53(прил. 4):22–7 [Aleksandrova EN, Nasonov EL. Immunogenicity inhibitors of tumor necrosis factor α in the treatment of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;53(Suppl 4):22–7 (In Russ.)].Ruiz-Esquide V, Zufferey P, Yagü e J, et al. Relationship between clinical remission and serum levels of tocilizumab in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):77. doi: 10.1136/annrheumdis-2015-eular.3444Ruiz-Esquide V, Zufferey P, Yagü e J, et al. Relationship between clinical remission and serum levels of tocilizumab in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):77. doi: 10.1136/annrheumdis-2015-eular.3444Hammer HB, Bolstad N, Warren DJ, et al. Patients with low serum adalimumab concentrations display poor ultrasonographic response to treatment; results of a follow-up study of patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):461. doi: 10.1136/annrheumdis-2015-eular.1328Hammer HB, Bolstad N, Warren DJ, et al. Patients with low serum adalimumab concentrations display poor ultrasonographic response to treatment; results of a follow-up study of patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):461. doi: 10.1136/annrheumdis-2015-eular.1328Opris D, Borangiu A, Gudu T, et al. Does serum drug level correlates with ultrasound evaluation in patients with rheumatoid arthritis treated with TNF antagonists? Ann Rheum Dis. 2015;74(Suppl 2):702. doi: 10.1136/annrheumdis-2015-eular.2844Opris D, Borangiu A, Gudu T, et al. Does serum drug level correlates with ultrasound evaluation in patients with rheumatoid arthritis treated with TNF antagonists? Ann Rheum Dis. 2015;74(Suppl 2):702. doi: 10.1136/annrheumdis-2015-eular.2844Paredes B, Plasencia C, Pascual-Salcedo D, et al. Influence of optimization of biological therapies on immunogenicity in a cohort of rheumatoid arthritis with low disease activity. Ann Rheum Dis. 2015;74(Suppl 2):458. doi: 10.1136/annrheumdis-2015-eular.5515Paredes B, Plasencia C, Pascual-Salcedo D, et al. Influence of optimization of biological therapies on immunogenicity in a cohort of rheumatoid arthritis with low disease activity. Ann Rheum Dis. 2015;74(Suppl 2):458. doi: 10.1136/annrheumdis-2015-eular.5515Denarie D, Rinaudo M, Thomas T, et al. Methotrexate reduced TNF bioactivity by anti-infliximab antibody prevention in rheumatoid arthritis patients treated with infliximab. Ann Rheum Dis. 2015;74(Suppl 2):459. doi: 10.1136/annrheumdis-2015-eular.3296Denarie D, Rinaudo M, Thomas T, et al. Methotrexate reduced TNF bioactivity by anti-infliximab antibody prevention in rheumatoid arthritis patients treated with infliximab. Ann Rheum Dis. 2015;74(Suppl 2):459. doi: 10.1136/annrheumdis-2015-eular.3296L’Ami M, Kneepkens E, Krieckaert C, et al. The effect of methotrexate in treatment with adalimumab and etanercept in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):708. doi: 10.1136/annrheumdis-2015-eular.2689L’Ami M, Kneepkens E, Krieckaert C, et al. The effect of methotrexate in treatment with adalimumab and etanercept in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2):708. doi: 10.1136/annrheumdis-2015-eular.2689Gottenberg JE, Morel J, Ravaud P, et al. Tolerance of rituximab, abatacept and tocilizumab in common practice: analysis of the 3 registries of the French society of rheumatology (AIR, ORA AND REGATE). Ann Rheum Dis. 2015;74(Suppl 2):78. doi: 10.1136/annrheumdis-2015-eular.3807Gottenberg JE, Morel J, Ravaud P, et al. Tolerance of rituximab, abatacept and tocilizumab in common practice: analysis of the 3 registries of the French society of rheumatology (AIR, ORA AND REGATE). Ann Rheum Dis. 2015;74(Suppl 2):78. doi: 10.1136/annrheumdis-2015-eular.3807Ozguler Y, Hatemi G, Ugurlu S, et al. Restarting biologics in patients who developed tuberculosis during anti TNF-alpha treatment. Ann Rheum Dis. 2015;74(Suppl 2):472. doi: 10.1136/annrheumdis-2015-eular.2512Ozguler Y, Hatemi G, Ugurlu S, et al. Restarting biologics in patients who developed tuberculosis during anti TNF-alpha treatment. Ann Rheum Dis. 2015;74(Suppl 2):472. doi: 10.1136/annrheumdis-2015-eular.2512Fang L, Liao Z, Lin Z, et al. Safety of adalimumab therapy in HbsAg carriers with rheumatoid arthritis: a prospective study. Ann Rheum Dis. 2015;74(Suppl 2):464. doi: 10.1136/annrheumdis-2015-eular.6487Fang L, Liao Z, Lin Z, et al. Safety of adalimumab therapy in HbsAg carriers with rheumatoid arthritis: a prospective study. Ann Rheum Dis. 2015;74(Suppl 2):464. doi: 10.1136/annrheumdis-2015-eular.6487

The authors declare that there are no conflicts of interest present.